An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease
A Haake, K Nguyen, L Friedman… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease
A Haake, K Nguyen, L Friedman… - Expert opinion on …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
A Haake, K Nguyen, L Friedman… - Expert Opinion on …, 2020 - europepmc.org
Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …
disorders with a prevalence in the US of about 5.7 million in 2018. With the disease burden …